Medication Summary
Bronchodilators may be used to encourage sputum expectoration; if underlying airflow is present, these agents may also improve ventilation. Some patients may require broad-spectrum antibiotics to treat the underlying infections, which may occur because of bronchial obstruction. N -acetylcysteine aerosols are not recommended because of the risk of bronchoconstriction and the lack of documented efficacy.
Bronchodilators
Class Summary
Decrease muscle tone in both the small and large airways in the lungs, thereby increasing ventilation. Includes subcutaneous medications, beta-adrenergic agents, methylxanthines, and anticholinergics.
Albuterol (Proventil, Ventolin)
Beta-agonist for bronchospasm refractory to epinephrine. Relaxes bronchial smooth muscle by action on beta-2 receptors, with little effect on cardiac muscle contractility. Most patients (even those with no measurable increase in expiratory flow) benefit from treatment. Inhaled beta-agonists initially are prescribed prn. Frequency may be increased; institute regular schedule in patients on anticholinergic drugs who are still symptomatic.
Available as a liquid for nebulizer, metered-dose inhalers (MDI), and dry-powder inhalers.
Metaproterenol (Alupent)
Relaxes bronchial smooth muscle by action on beta-2 receptors, with little effect on cardiac muscle contractility. Most patients (even those with no measurable increase in expiratory flow) benefit from treatment. Inhaled beta-agonists initially are prescribed prn. Frequency may be increased; institute regular schedule in patients on anticholinergic drugs who are still symptomatic.
Available as a liquid for nebulizer, MDI, and dry-powder inhaler.
Antibiotics
Class Summary
To treat underlying bronchitis or postobstructive infection.
Cefuroxime (Zinacef)
Second-generation cephalosporin maintains gram-positive activity of first-generation cephalosporins; adds activity against Proteus mirabilis, Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, and Moraxella catarrhalis.
Condition of patient, severity of infection, and susceptibility of microorganism determine proper dose and route of administration.
Cefaclor (Ceclor)
Second-generation cephalosporin indicated for infections caused by susceptible gram-positive cocci and gram-negative rods.
Determine proper dosage and route based on condition of patient, severity of infection, and susceptibility of causative organisms.
Mucolytic agents
Class Summary
N -acetylcysteine is only recommended for direct instillation via fiberoptic bronchoscopy or in an intubated patient. Therapy with mucolytics may promote sputum removal of thick mucous plugs and, therefore, helps treat atelectasis in many patients. Inhaled recombinant human deoxyribonuclease is a mucolytic agent successfully used in patients with cystic fibrosis.
N-acetylcysteine (Mucomyst)
Inhalations may be tried to encourage sputum expectoration in patients with tenacious sputum and mucous plugging.
Dornase alfa (Pulmozyme)
Cleaves and depolymerizes extracellular DNA and separates DNA from proteins. This allows endogenous proteolytic enzymes to break down the proteins; thus, decreasing viscoelasticity and surface tension of purulent sputum.
Rosenbloom SA, Ravin CE, Putman CE, et al. Peripheral middle lobe syndrome. Radiology. 1983;149:17-21. [Medline]. [Full Text].
Priftis KN, Mermiri D, Papadopoulou A, Anthracopoulos MB, Vaos G, Nicolaidou P. The role of timely intervention in middle lobe syndrome in children. Chest. Oct 2005;128(4):2504-10. [Medline].
Chen HA, Lai SL, Kwang WK, Liu JC, Chen CH, Huang DF. Middle lobe syndrome as the pulmonary manifestation of primary Sjogren's syndrome. Med J Aust. Mar 20 2006;184(6):294-5. [Medline].
Reinius H, Jonsson L, Gustafsson S, et al. Prevention of atelectasis in morbidly obese patients during general anesthesia and paralysis: a computerized tomography study. Anesthesiology. Nov 2009;111(5):979-87. [Medline].
Mavros MN, Velmahos GC, Falagas ME. Atelectasis as a cause of postoperative fever: where is the clinical evidence?. Chest. Aug 2011;140(2):418-24. [Medline].
Proto AV, Tocino I. Radiographic manifestations of lobar collapse. Semin Roentgenol. Apr 1980;15(2):117-73. [Medline].
Kattan KR, Eyler WR, Felson B. The juxtaphrenic peak in upper lobe collapse. Semin Roentgenol. Apr 1980;15(2):187-93. [Medline].
Partap VA. The comet tail sign. Radiology. Nov 1999;213(2):553-4. [Medline].
[Guideline] McCool FD, Rosen MJ. Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. Chest. Jan 2006;129(1 Suppl):250S-259S. [Medline].
Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ. DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care. Aug 2005;9(4):R351-6. [Medline].
Kato K, Sato N, Takeda S, et al. Marked improvement of extensive atelectasis by unilateral application of the RTX respirator in elderly patients. Intern Med. 2009;48(16):1419-23. [Medline].
Franken EA Jr, Klatte EC. Atypical (peripheral) upper lobe collapse. Ann Radiol (Paris). Jan-Feb 1977;20(1):87-93. [Medline].
Herold CJ, Kuhlman JE, Zerhouni EA. Pulmonary atelectasis: signal patterns with MR imaging. Radiology. Mar 1991;178(3):715-20. [Medline].
Proto AV. Lobar collapse: basic concepts. Eur J Radiol. Aug 1996;23(1):9-22. [Medline].
Pryor JA. Physiotherapy for airway clearance in adults. Eur Respir J. Dec 1999;14(6):1418-24. [Medline].
Reading M. Chest X-ray quiz. Lung atelectasis. Intensive Crit Care Nurs. Dec 2005;21(6):361-2. [Medline].
Schindler MB. Treatment of atelectasis: where is the evidence?. Crit Care. Aug 2005;9(4):341-2. [Medline].
Stark P. Round atelectasis: another pulmonary pseudotumor. Am Rev Respir Dis. Feb 1982;125(2):248-50. [Medline].
Stark P, Leung A. Effects of lobar atelectasis on the distribution of pleural effusion and pneumothorax. J Thorac Imaging. Spring 1996;11(2):145-9. [Medline].
Westcott JL, Cole S. Plate atelectasis. Radiology. Apr 1985;155(1):1-9. [Medline].
Woodring JH, Reed JC. Radiographic manifestations of lobar atelectasis. J Thorac Imaging. Spring 1996;11(2):109-44. [Medline].

